Business Context and Reporting Period
Company: Healthcare Acquisition Corp. (Note: The filing metadata references "Altimmune, Inc.", but the document text explicitly identifies the registrant as "Healthcare Acquisition Corp.", a blank check company formed on April 25, 2005).
Reporting Period: Fiscal year ended December 31, 2005 (Inception to December 31, 2005).
Business Model: The Company is a "shell company" organized to acquire one or more domestic or international operating businesses in the healthcare industry. As of the filing date, the Company has no substantive operations, no revenue from commercial activities, and has not identified a specific target business. Its primary activity is the search for a business combination.
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Assets | $70,086,750 |
| Cash and Cash Equivalents | $1,398,181 |
| Investments Held in Trust | $68,636,069 |
| Total Liabilities | $410,535 |
| Stockholders' Equity | $56,097,408 |
| Net Income | $277,295 |
| Basic EPS | $0.04 |
| Diluted EPS | $0.03 |
Revenue: Total revenue of $586,074 consists entirely of interest income ($19,548) and interest/dividend income from the Trust Fund ($566,526). There is no operating revenue.
Expenses: Total expenses were $260,779, primarily driven by capital-based taxes ($115,000), management fees ($37,986), and general administrative costs.
Liquidity: The Company holds approximately $1.4 million in working capital outside the trust to fund operations and search for a target. The Trust Fund holds approximately $68.6 million, restricted for use in a business combination or liquidation.
Material Changes and IPO Proceeds
The Company consummated its Initial Public Offering (IPO) on August 3, 2005, selling 9,000,000 units, followed by the exercise of an overallotment option for 400,000 units on August 16, 2005.
- Gross Proceeds: $75,200,000.
- Net Proceeds: Approximately $69,468,000 after deducting underwriting discounts ($4,512,000) and offering expenses.
- Trust Allocation: $67,928,000 (approx. $7.23 per share) was deposited into a Trust Account.
- Working Capital: $1,540,000 was retained outside the trust for transaction costs and administrative expenses.
There is no prior comparable period for operating results as the Company was formed in April 2005 and had no operations prior to the IPO.
Outlook, Risks, and Contingencies
Outlook and Guidance: The Company has 18 months from the IPO consummation (until February 3, 2007) to complete a business combination. If extended criteria are met, this period may be extended to 24 months. If no combination is completed, the Company will liquidate and distribute the Trust Fund to public stockholders.
Key Risks:
- Liquidation Risk: If the Company fails to complete a business combination, public stockholders will receive approximately $7.23 per share (plus interest), which is less than the $8.00 IPO price. Warrants will expire worthless.
- Target Selection: The Company has not identified a target. Investors cannot evaluate the merits or risks of a future target business.
- Competition: Intense competition from other blank check companies and private equity firms for healthcare targets.
- Regulatory Risk: Future operations will be subject to extensive healthcare regulations (FDA, Medicare/Medicaid) which could increase costs or limit revenue.
- Conflicts of Interest: Officers and directors have other business interests and may have conflicts in allocating time or selecting targets.
Unusual Items: The Company is classified as a "shell company." The financial statements reflect a "development stage" entity with no commercial operations.
Investor Verification Checklist
- Trust Fund Status: Verify the current balance of the Trust Account and accrued interest to confirm the liquidation value per share.
- Extension Deadlines: Confirm the specific deadline for completing a business combination (February 3, 2007, or extended to 24 months) and whether extension criteria have been met.
- Target Identification: Monitor for any announcements regarding a definitive agreement with a target business, as none exists as of this filing.
- Related Party Transactions: Review the $7,500 monthly fee paid to an affiliate (Equity Dynamics, Inc.) for office space and administrative services.
- Warrant Terms: Note that warrants are exercisable at $6.00 per share but only after a business combination or one year post-IPO, whichever is later.